NPPB and Nephropathy: Esaxerenone may be a treatment option that reduces the risk of both cardiovascular and renal events, considering the role of UACR as a risk factor of cardiac and renal events [44–46] and NT-proBNP as a predictor of cardiovascular risk and kidney damage [47–49].